ClinicalTrials.gg
CompletedNCT01563926Updated Feb 27, 2017

Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

A Phase 3 interventional study of somatropin in Growth Hormone Disorder, Growth Hormone Deficiency in Children and Genetic Disorder, sponsored by Novo Nordisk A/S. Completed at 6 sites in Israel. Per ClinicalTrials.gov, last updated 2017-02-27.

Primary conditionTurner SyndromeRegistry: Genetic Diseases, InbornReclassifiedWhy we changed it
Registry
Genetic Diseases, Inborn — the first condition term the registry derived for this study.
ClinicalTrials.gg
Turner Syndrome
Why
  1. The study's listed conditions name Turner Syndrome, a narrower term within Genetic Diseases, Inborn.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 11 years 5 months after the study started (first participant enrolled Oct 2000, registered Mar 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.

Enrollment
3rd of 14
168 · median 108
Started
2000
the only one that year
Phase 3
6 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
4 of 14
Novo Nordisk A/S

Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 3rd largest by enrollment, is the only one that started in 2000, is one of 6 in phase 3, and was the 12th registered.

Turner Syndrome

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

Browse Turner Syndrome studies →

Open to participants now

None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing Human Growth Hormone in Turner Syndrome as a file.
02

Study summary

This trial is conducted in Asia. The aim of this trial is to evaluate the new liquid somatropin formulation in children with growth hormone deficiency.

03

Conditions studied

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children
  • Genetic Disorder
  • Turner Syndrome

Browse trials for

04

In context

Turner Syndrome Reclassified

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

This study's enrollment of 168 is above the median of 67 across 52 interventional studies indexed under Turner Syndrome.

Browse Turner Syndrome studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Turner Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written by patient and/or guardian/parents
  • Patients with one of the following diagnosis: Growth failure due to growth hormone deficiency (GHD), Turner syndrome, or growth retardation in children with chronic renal disorders
  • Patients who are willing to inject themselves and answer questionnaires or young patients whose parents/guardian are willing to inject their child and answer questionnaires
  • Patients on growth hormone therapy for at least 6 weeks before entering the trial

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breast feeding women
  • Suspected or known allergy to trial product
  • Other daily injection therapy (non-growth hormone, e.g insulin-therapy)
  • Participating in any other trial involving other products within the last 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Somatropin

    Drug: somatropin

Interventions

  • Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)

07

What researchers measure

Primary outcomes

  1. Patient acceptance of the new liquid growth hormone formulation

Secondary outcomes

  1. Number of Adverse Events (AE)

  2. Number of Serious Adverse Events (SAE)

08

Study locations

6 sites
  • Novo Nordisk Investigational Site
    Afula, 18101, Israel
  • Novo Nordisk Investigational Site
    Beer Sheva, 84101, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91240, Israel
  • Novo Nordisk Investigational Site
    Petah Tikva, 49202, Israel
  • Novo Nordisk Investigational Site
    Rehovot, 76100, Israel
  • Novo Nordisk Investigational Site
    Tel - Aviv, 64293, Israel
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2000 to primary completion in Oct 2002, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2012
First posted
Mar 27, 2012
StartActual
Oct 23, 2000
Primary completionActual
Oct 10, 2002
CompletionActual
Oct 10, 2002
Last update
Feb 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01563926
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 27, 2012
Start date
Oct 23, 2000
Primary completion
Oct 10, 2002
Completion
Oct 10, 2002
Last update
Feb 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion